The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis

Treatment resistance, the major challenge in the management of advanced prostate cancer, is in part based on resistance to apoptosis. The Inhibitor of Apoptosis (IAP) protein family is thought to play key roles in survival and drug resistance of cancer via inhibition of apoptosis. Of the IAP family members, cIAP1, cIAP2, XIAP and survivin are known to be up-regulated in prostate cancer. BIRC6, a much less studied IAP member, was recently shown to be elevated in castration-resistant prostate cancer (CRPC). In the present study, we showed a correlation between elevated BIRC6 expression in clinical prostate cancer specimens and poor patient prognostic factors, as well as co-upregulation of certain IAP members. In view of this, we designed antisense oligonucleotides that simultaneously target BIRC6 and another co-upregulated IAP member (dASOs). Two dASOs, targeting BIRC6+cIAP1 and BIRC6+survivin, showed substantial inhibition of CRPC cell proliferation, exceeding that obtained with single BIRC6 targeting. The growth inhibition was associated with increased apoptosis, cell cycle arrest and suppression of NFkB activation. Moreover, treatment with either dASO led to significantly lower viable tumor volume in vivo, without major host toxicity. This study shows that BIRC6-based dual IAP-targeting ASOs represent potential novel therapeutic agents against advanced prostate cancer.

[1]  M. Rubin,et al.  High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. , 2014, Cancer research.

[2]  F. Saad,et al.  Overview of the latest treatments for castration-resistant prostate cancer , 2013, Nature Reviews Urology.

[3]  K. Pienta,et al.  The 19th annual Prostate Cancer Foundation scientific retreat. , 2013, Cancer research.

[4]  N. Kyprianou,et al.  Targeting caspases in cancer therapeutics , 2013, Biological chemistry.

[5]  D. Novack,et al.  Anti-cancer IAP antagonists promote bone metastasis: a cautionary tale , 2013, Journal of Bone and Mineral Metabolism.

[6]  Yuzhuo Wang,et al.  Lessons from in-vivo models of castration-resistant prostate cancer , 2013, Current opinion in urology.

[7]  M. Gleave,et al.  BIRC6 Protein, an Inhibitor of Apoptosis: Role in Survival of Human Prostate Cancer Cells , 2013, PloS one.

[8]  S. Lam,et al.  Elevated Expression of BIRC6 Protein in Non–Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Xiaodong Bai,et al.  A Discrete Ubiquitin-Mediated Network Regulates the Strength of NOD2 Signaling , 2012, Molecular and Cellular Biology.

[10]  D. Vučić,et al.  The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. , 2012, Experimental oncology.

[11]  F. Speleman,et al.  Identification of BIRC6 as a novel intervention target for neuroblastoma therapy , 2012, BMC Cancer.

[12]  N. Zaffaroni,et al.  Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways , 2012, Clinical Cancer Research.

[13]  S. Keir,et al.  Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program , 2012, Pediatric blood & cancer.

[14]  Shaomeng Wang,et al.  Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment , 2011, Molecular Cancer Therapeutics.

[15]  P. Iversen,et al.  Antisense Inhibition of Survivin Expression as a Cancer Therapeutic , 2011, Molecular Cancer Therapeutics.

[16]  M. Gleave,et al.  Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo , 2011, Molecular Cancer Therapeutics.

[17]  Pascal Meier,et al.  IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer , 2010, Nature Reviews Cancer.

[18]  L. Languino,et al.  IAP regulation of metastasis. , 2010, Cancer cell.

[19]  K. Pienta,et al.  CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. , 2009, Neoplasia.

[20]  J. B. Garrison,et al.  XIAP mediates NOD signaling via interaction with RIP2 , 2009, Proceedings of the National Academy of Sciences.

[21]  Q. Zeng,et al.  Genetic deletion of faim reveals its role in modulating c-FLIP expression during CD95-mediated apoptosis of lymphocytes and hepatocytes , 2009, Cell Death and Differentiation.

[22]  K. Pienta,et al.  Molecularly Targeted Radiosensitization of Human Prostate Cancer by Modulating Inhibitor of Apoptosis , 2008, Clinical Cancer Research.

[23]  S. Baird,et al.  IAP-targeted therapies for cancer , 2008, Oncogene.

[24]  W. Fairbrother,et al.  c-IAP1 and c-IAP2 Are Critical Mediators of Tumor Necrosis Factor α (TNFα)-induced NF-κB Activation* , 2008, Journal of Biological Chemistry.

[25]  R. Korneluk,et al.  The RING domain of cIAP1 mediates the degradation of RING-bearing inhibitor of apoptosis proteins by distinct pathways. , 2008, Molecular biology of the cell.

[26]  C. Qian,et al.  Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil , 2008, Gene Therapy.

[27]  Christian Pohl,et al.  Final Stages of Cytokinesis and Midbody Ring Formation Are Controlled by BRUCE , 2008, Cell.

[28]  Hee-Jin Kim,et al.  Overexpression of Apollon, an Antiapoptotic Protein, Is Associated with Poor Prognosis in Childhood De novo Acute Myeloid Leukemia , 2007, Clinical Cancer Research.

[29]  P. Carinci,et al.  Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. , 2006, International journal of oncology.

[30]  M. Gleave,et al.  Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer , 2005, Cancer Chemotherapy and Pharmacology.

[31]  D. Stokoe,et al.  Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi. , 2005, The Biochemical journal.

[32]  T. Tsuruo,et al.  HtrA2 cleaves Apollon and induces cell death by IAP-binding motif in Apollon-deficient cells. , 2005, Biochemical and biophysical research communications.

[33]  W. Skarnes,et al.  The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Goldberg,et al.  The Membrane-associated Inhibitor of Apoptosis Protein, BRUCE/Apollon, Antagonizes Both the Precursor and Mature Forms of Smac and Caspase-9* , 2005, Journal of Biological Chemistry.

[35]  S. Agrawal,et al.  Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics , 2004, Oncogene.

[36]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[37]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[38]  Seamus J. Martin.  An Apollon vista of death and destruction , 2004, Nature Cell Biology.

[39]  T. Noda,et al.  Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function , 2004, Nature Cell Biology.

[40]  S. Jentsch,et al.  Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. , 2004, Molecular cell.

[41]  A. Goldberg,et al.  Nrdp1‐mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis , 2004, The EMBO journal.

[42]  A. Vitiello,et al.  Elevated expression of inhibitor of apoptosis proteins in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  G. Gores,et al.  Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ * , 2002, The Journal of Biological Chemistry.

[44]  N. Dias,et al.  Antisense oligonucleotides: basic concepts and mechanisms. , 2002, Molecular cancer therapeutics.

[45]  J. Downward,et al.  The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. , 2000, Journal of cell science.

[46]  Fengzhi Li,et al.  Pleiotropic cell-division defects and apoptosis induced by interference with survivin function , 1999, Nature Cell Biology.

[47]  T. Tsuruo,et al.  A human IAP-family gene, apollon, expressed in human brain cancer cells. , 1999, Biochemical and biophysical research communications.

[48]  J C Reed,et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.

[49]  B. Eigl,et al.  Targeting the apoptosis pathway in prostate cancer. , 2013, Cancer journal.

[50]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[51]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.